Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATNXNASDAQ:ESPRNASDAQ:PHATNASDAQ:TBPHNASDAQ:ZGNX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNXAthenex$0.95$0.20▼$23.80$1.76M1.36194,316 shs1.88 million shsESPREsperion Therapeutics$1.95+4.3%$2.46$0.70▼$3.40$354.18M0.849.53 million shs7.35 million shsPHATPhathom Pharmaceuticals$8.97-5.4%$9.65$6.07▼$17.02$554.81M0.63865,061 shs590,192 shsTBPHTheravance Biopharma$9.34+1.5%$9.01$8.21▼$11.98$446.75M0.36399,447 shs433,019 shsZGNXZogenix$26.68$26.52$11.03▼$26.90$1.50B0.893.76 million shs94 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNXAthenex0.00%0.00%0.00%0.00%-86.09%ESPREsperion Therapeutics+4.28%-8.88%-10.96%-3.47%+48.85%PHATPhathom Pharmaceuticals-5.38%-11.54%-1.64%+19.76%-16.32%TBPHTheravance Biopharma+1.52%-2.81%+3.66%-1.37%-19.55%ZGNXZogenix0.00%0.00%0.00%0.00%0.00%Biden’s $374B Giveaway Into This Sector (Ad)Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full storyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNXAthenexN/AN/AN/AN/AN/AN/AN/AN/AESPREsperion Therapeutics3.6217 of 5 stars3.22.00.03.93.30.80.6PHATPhathom Pharmaceuticals1.7487 of 5 stars3.40.00.00.01.94.20.6TBPHTheravance Biopharma2.0707 of 5 stars3.52.00.00.02.02.50.6ZGNXZogenixN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNXAthenexN/AN/AN/AN/AESPREsperion Therapeutics2.40Hold$9.33378.63% UpsidePHATPhathom Pharmaceuticals2.75Moderate Buy$21.33137.83% UpsideTBPHTheravance Biopharma3.00Buy$20.50119.49% UpsideZGNXZogenixN/AN/AN/AN/ACurrent Analyst RatingsLatest TBPH, PHAT, ZGNX, ESPR, and ATNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/19/2024PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.004/12/2024TBPHTheravance BiopharmaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/11/2024PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.004/10/2024ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.004/1/2024PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.003/25/2024ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.003/25/2024ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/22/2024PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.003/15/2024PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.002/28/2024ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $16.002/27/2024ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00(Data available from 4/20/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNXAthenex$102.82M0.00N/AN/A($3.07) per share0.00ESPREsperion Therapeutics$116.33M3.17N/AN/A($3.85) per share-0.51PHATPhathom Pharmaceuticals$680K771.95N/AN/A($1.27) per share-7.06TBPHTheravance Biopharma$57.42M7.90N/AN/A$4.28 per share2.18ZGNXZogenix$81.69M18.36N/AN/A$6.64 per share4.02Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNXAthenex-$103.43M-$15.88N/AN/AN/A-86.31%-727.79%-44.44%N/AESPREsperion Therapeutics-$209.25M-$2.12N/A6.29N/A-179.87%N/A-91.62%5/14/2024 (Estimated)PHATPhathom Pharmaceuticals-$201.59M-$3.88N/AN/AN/AN/AN/A-63.40%5/8/2024 (Estimated)TBPHTheravance Biopharma-$55.19M-$0.97N/AN/AN/A-96.12%-19.31%-12.03%5/13/2024 (Estimated)ZGNXZogenix-$209.38M-$4.07N/AN/AN/A-278.38%-91.20%-43.60%N/ALatest TBPH, PHAT, ZGNX, ESPR, and ATNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023PHATPhathom Pharmaceuticals-$0.92-$0.80+$0.12-$0.21$0.93 million$0.68 million 2/27/202412/31/2023ESPREsperion Therapeutics-$0.53-$0.50+$0.03-$0.50$26.84 million$32.25 million 2/26/2024Q4 2023TBPHTheravance Biopharma-$0.15-$0.17-$0.02-$0.17$17.49 million$17.57 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNXAthenexN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/AZGNXZogenixN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNXAthenex3.081.090.72ESPREsperion TherapeuticsN/A1.290.87PHATPhathom PharmaceuticalsN/A10.2510.22TBPHTheravance BiopharmaN/A5.395.39ZGNXZogenix0.883.634.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNXAthenex30.48%ESPREsperion Therapeutics47.39%PHATPhathom Pharmaceuticals99.01%TBPHTheravance Biopharma99.10%ZGNXZogenixN/AInsider OwnershipCompanyInsider OwnershipATNXAthenex9.20%ESPREsperion Therapeutics0.60%PHATPhathom Pharmaceuticals27.10%TBPHTheravance Biopharma6.90%ZGNXZogenix4.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATNXAthenex6528.66 million7.87 millionOptionableESPREsperion Therapeutics240189.40 million188.27 millionOptionablePHATPhathom Pharmaceuticals45258.52 million42.66 millionOptionableTBPHTheravance Biopharma35948.56 million45.21 millionOptionableZGNXZogenix21856.23 million53.92 millionOptionableTBPH, PHAT, ZGNX, ESPR, and ATNX HeadlinesSourceHeadlineHwasung Industrial Co Ltd 002460morningstar.com - March 23 at 1:30 AMOrally Inhaled Dihydroergotaminemedscape.com - February 13 at 4:11 PMMRI in Headachemedscape.com - August 25 at 10:47 PMKratom: What We Knowmedscape.com - August 13 at 5:03 PMAlcon (NYSE: ALC)fool.com - July 6 at 8:34 PMLongeveron Inc Ordinary Shares - Class Amorningstar.com - May 21 at 12:24 AMDravet Syndrome Market Report 2032: Epidemiology Data, Pipeline ... - Digital Journalnews.google.com - May 10 at 11:58 PMGlobal Needle Free Diabetes Management Market Size 2023 ... - The Northwestern Examinernews.google.com - May 8 at 2:44 PMGlobal Needle-Free Drug Delivery Systems Market New ... - The Northwestern Examinernews.google.com - May 8 at 2:44 PMNeedle Free Injection Systems Market Size Reach Valuation of USD 519.3 Million in 2030 - Emergen Research - openPRnews.google.com - May 4 at 4:03 PMNeedle Free Diabetes Management Market Forecast 2023 – 2032 ... - Taiwan Newsnews.google.com - April 28 at 12:42 PMThe Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine Headachemedscape.com - April 25 at 2:50 PMLong-Acting Injectable Antipsychotics Market 2023-2033: Global ... - Taiwan Newsnews.google.com - April 24 at 9:21 AMAnti-epileptic Drugs Market Expected to Expand at a Steady 2023 ... - Digital Journalnews.google.com - April 24 at 9:21 AMDravet Syndrome Pipeline Assessment (2023 Updates) | In-depth ... - Digital Journalnews.google.com - April 20 at 12:29 AMForm SC 14D9/A Provention Bio, Inc. Filed by: Provention Bio, Inc. - StreetInsider.comnews.google.com - April 19 at 7:28 PMDEA lifts Dravet therapy Fintepla's controlled substance status |... - Dravet Syndrome Newsnews.google.com - April 18 at 3:52 PMUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - Longview News-Journalnews.google.com - April 17 at 7:30 PMSubcutaneous Medicine Delivery Devices Market is poised to grow ... - Digital Journalnews.google.com - April 17 at 7:30 PMEpilepsy Market to Observe Utmost CAGR of 7.78% by 2028, Size ... - Digital Journalnews.google.com - April 17 at 9:27 AMUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - PR Newswirenews.google.com - April 17 at 9:27 AMLennox Gastaut Syndrome Market to Witness Growth by 2032 | Companies-GlaxoSmithKline, Meda Pharmaceuticals, Ro - openPRnews.google.com - April 14 at 8:40 AMNeedle-Free Injectors Market Robust Expansion is expected to 2030 - Digital Journalnews.google.com - April 13 at 5:40 PMNew Trends of Long-acting Injectable Medications Market Demand: Insights and Analysis from Latest Research Rep - openPRnews.google.com - April 12 at 1:29 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAthenexNASDAQ:ATNXAthenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.Esperion TherapeuticsNASDAQ:ESPREsperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Phathom PharmaceuticalsNASDAQ:PHATPhathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Theravance BiopharmaNASDAQ:TBPHTheravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.ZogenixNASDAQ:ZGNXZogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.